| mRNA |
barasertib |
CTRPv2 |
pan-cancer |
AAC |
0.15 |
2e-06 |
| mRNA |
BRD-K11533227 |
CTRPv2 |
pan-cancer |
AAC |
0.17 |
5e-06 |
| mRNA |
doxorubicin:navitoclax (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
8e-06 |
| mRNA |
Doxorubicin |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
2e-05 |
| mRNA |
navitoclax:sorafenib (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.14 |
9e-05 |
| mRNA |
Mitomycin-C |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0001 |
| mRNA |
epigallocatechin-3-monogallate |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0006 |
| mRNA |
Cytarabine |
CTRPv2 |
pan-cancer |
AAC |
0.096 |
0.0007 |
| mRNA |
carboplatin:etoposide (40:17 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.1 |
0.0008 |
| mRNA |
carboplatin:UNC0638 (2:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.13 |
0.0008 |